Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Urothelial Cancer × Docetaxel × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 405 Carcinoma, Non-Small-Cell Lung 369 Prostatic Neoplasms 244 Lung Neoplasms 142 Stomach Neoplasms 119 Neoplasms 94 Squamous Cell Carcinoma of Head and Neck 92 Neoplasm Metastasis 77 Head and Neck Neoplasms 76 Esophageal Neoplasms 61 Ovarian Neoplasms 48 Pancreatic Neoplasms 36 Urinary Bladder Neoplasms 34 Sarcoma 34 Nasopharyngeal Carcinoma 31 Triple Negative Breast Neoplasms 28 Carcinoma, Squamous Cell 27 Adenocarcinoma 24 Carcinoma, Ovarian Epithelial 23 Adenocarcinoma of Lung 22 Esophageal Squamous Cell Carcinoma 21 Adenocarcinoma Of Esophagus 21 Recurrence 20 Carcinoma, Transitional Cell 20 Breast Neoplasms, Male 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Melanoma 17 Fallopian Tube Neoplasms 17 Carcinoma 16 Unspecified Adult Solid Tumor, Protocol Specific 15

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03390504 2026-02-02

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡